Evaluation Of Efficacy And Medical Economics For Recombinant Human Granulocyte Colony-stimulating Factor In Therapy Of Induction For Acute Myeloid Leukemia In Childhood

Objective: To evaluate the efficacy of recombinant human granulocyte colony-stimulating factor(rh G-CSF)in the induction and remission of childhood acute myeloid leukemia(AML)and its hygienic and economic valve.Methods:Retrospectively analyses clinical data of 181 children who suffered from AML and received induction chemotherapy between 2007.1to 2015.1.these patients were classified into treatment group(rh G-CSF was administered,69 cases)and control group(rh G-CSF was ignored,112cases),medical and economics index were recorded and evaluated.Medical index included duration of neutrophil rescue and fever,incidence of infection,complete remission rate,economics index included cost and its composition ratio.Results:1.Age at diagnosis or WBC count,gender and lowest value of acute neutrophil count(ANC)after chemotherapy did not differ between the two groups(P>0.05).2.The redcution period of granulocytes in the study group was shorter than that in the contorl group(P<0.05),and the difference was statistically significant(P<0.05).The period of Granulocyte deficiency in the treatment group was shorter than that in the control group,but there was no significant difference(P>0.05).3.The CR rates of the two groups were 84.82% and 79.71%respectively,and there was was no signicant difference(P>0.05).4.There was was no signicant difference in the incidence of pneumonia and gastrointestinal tract infection between the two groups after chemotherapy(P>0.05),but the incidence of sepsis in the control group was higher than that in the treatment group,and the time of fever associated with granulocyte deficiency in the contorl group were shorter than those in the treatment group(P<0.05).5.The average length of hospitalization days in the treatment group was higher than that in the control group(P<0.05),and there was no significant difference in total hospitalization expensense and drug expenditure between the two groups(P>0.05).Conclusion: Rh G-csf can significantly shorten the time of indcution and remission in children with AML after chemotherapy,but it cannot shorten the critical period for severe infection,reduce the risk of severe infection or increase the CR rate in children with AML.Moreover,there is no significant improvement in the relevant hygienic and economics indicators of rh G-csf treatment,it is unsuitable for conventional administration of rh G-CSF to AML patients with neutropenia after chemotherapy of induction.